vs
Side-by-side financial comparison of Vita Coco Company, Inc. (COCO) and NATURES SUNSHINE PRODUCTS INC (NATR). Click either name above to swap in a different company.
Vita Coco Company, Inc. is the larger business by last-quarter revenue ($179.8M vs $123.8M, roughly 1.5× NATURES SUNSHINE PRODUCTS INC). Vita Coco Company, Inc. runs the higher net margin — 17.0% vs 3.3%, a 13.6% gap on every dollar of revenue. On growth, Vita Coco Company, Inc. posted the faster year-over-year revenue change (37.3% vs 4.7%). Over the past eight quarters, Vita Coco Company, Inc.'s revenue compounded faster (11.7% CAGR vs 5.6%).
The Vita Coco Company, doing business simply as Vita Coco, is an American beverage company which mainly sells coconut water. The largest brand globally in coconut/plant waters, Vita Coco has operations in 31 countries as of 2016. It is a benefit corporation. The company is owned by All Market Inc.
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
COCO vs NATR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $179.8M | $123.8M |
| Net Profit | $30.5M | $4.1M |
| Gross Margin | 39.9% | 72.5% |
| Operating Margin | 18.7% | 4.3% |
| Net Margin | 17.0% | 3.3% |
| Revenue YoY | 37.3% | 4.7% |
| Net Profit YoY | 61.4% | 1379.4% |
| EPS (diluted) | $0.50 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $179.8M | — | ||
| Q4 25 | $127.8M | $123.8M | ||
| Q3 25 | $182.3M | $128.3M | ||
| Q2 25 | $168.8M | $114.8M | ||
| Q1 25 | $130.9M | $113.2M | ||
| Q4 24 | $127.3M | $118.2M | ||
| Q3 24 | $132.9M | $114.6M | ||
| Q2 24 | $144.1M | $110.6M |
| Q1 26 | $30.5M | — | ||
| Q4 25 | $5.5M | $4.1M | ||
| Q3 25 | $24.0M | $5.3M | ||
| Q2 25 | $22.9M | $5.3M | ||
| Q1 25 | $18.9M | $4.7M | ||
| Q4 24 | $3.4M | $-321.0K | ||
| Q3 24 | $19.3M | $4.3M | ||
| Q2 24 | $19.1M | $1.3M |
| Q1 26 | 39.9% | — | ||
| Q4 25 | 34.9% | 72.5% | ||
| Q3 25 | 37.7% | 73.3% | ||
| Q2 25 | 36.3% | 71.7% | ||
| Q1 25 | 36.7% | 72.1% | ||
| Q4 24 | 32.5% | 72.0% | ||
| Q3 24 | 38.8% | 71.3% | ||
| Q2 24 | 40.8% | 71.4% |
| Q1 26 | 18.7% | — | ||
| Q4 25 | 8.0% | 4.3% | ||
| Q3 25 | 15.3% | 7.0% | ||
| Q2 25 | 14.9% | 3.7% | ||
| Q1 25 | 14.7% | 5.4% | ||
| Q4 24 | 3.4% | 3.8% | ||
| Q3 24 | 15.5% | 4.6% | ||
| Q2 24 | 20.8% | 5.1% |
| Q1 26 | 17.0% | — | ||
| Q4 25 | 4.3% | 3.3% | ||
| Q3 25 | 13.2% | 4.2% | ||
| Q2 25 | 13.6% | 4.6% | ||
| Q1 25 | 14.4% | 4.2% | ||
| Q4 24 | 2.6% | -0.3% | ||
| Q3 24 | 14.5% | 3.8% | ||
| Q2 24 | 13.2% | 1.2% |
| Q1 26 | $0.50 | — | ||
| Q4 25 | $0.10 | $0.23 | ||
| Q3 25 | $0.40 | $0.30 | ||
| Q2 25 | $0.38 | $0.28 | ||
| Q1 25 | $0.31 | $0.25 | ||
| Q4 24 | $0.06 | $-0.02 | ||
| Q3 24 | $0.32 | $0.23 | ||
| Q2 24 | $0.32 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $201.9M | $93.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $352.2M | $161.6M |
| Total Assets | $488.3M | $261.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $201.9M | — | ||
| Q4 25 | $196.9M | $93.9M | ||
| Q3 25 | $203.7M | $95.6M | ||
| Q2 25 | $167.0M | $81.3M | ||
| Q1 25 | $153.6M | $86.5M | ||
| Q4 24 | $164.7M | $84.7M | ||
| Q3 24 | $156.7M | $78.7M | ||
| Q2 24 | $150.1M | $68.7M |
| Q1 26 | $352.2M | — | ||
| Q4 25 | $331.5M | $161.6M | ||
| Q3 25 | $323.7M | $166.7M | ||
| Q2 25 | $296.9M | $163.7M | ||
| Q1 25 | $277.9M | $167.1M | ||
| Q4 24 | $258.8M | $161.0M | ||
| Q3 24 | $252.1M | $162.6M | ||
| Q2 24 | $232.0M | $156.4M |
| Q1 26 | $488.3M | — | ||
| Q4 25 | $461.2M | $261.1M | ||
| Q3 25 | $461.3M | $264.8M | ||
| Q2 25 | $421.1M | $254.9M | ||
| Q1 25 | $384.0M | $252.7M | ||
| Q4 24 | $362.4M | $240.9M | ||
| Q3 24 | $353.1M | $245.3M | ||
| Q2 24 | $323.0M | $235.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $9.9M |
| Free Cash FlowOCF − Capex | — | $7.6M |
| FCF MarginFCF / Revenue | — | 6.1% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | — | $28.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-3.9M | $9.9M | ||
| Q3 25 | $39.1M | $18.5M | ||
| Q2 25 | $21.8M | $4.3M | ||
| Q1 25 | $-9.8M | $2.6M | ||
| Q4 24 | $6.9M | $12.2M | ||
| Q3 24 | $9.3M | $9.6M | ||
| Q2 24 | $26.9M | $1.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-7.1M | $7.6M | ||
| Q3 25 | $35.6M | $16.8M | ||
| Q2 25 | $20.9M | $3.0M | ||
| Q1 25 | $-10.4M | $1.5M | ||
| Q4 24 | $6.8M | $10.0M | ||
| Q3 24 | $8.9M | $7.9M | ||
| Q2 24 | $26.6M | $-2.0M |
| Q1 26 | — | — | ||
| Q4 25 | -5.6% | 6.1% | ||
| Q3 25 | 19.6% | 13.1% | ||
| Q2 25 | 12.4% | 2.6% | ||
| Q1 25 | -7.9% | 1.3% | ||
| Q4 24 | 5.3% | 8.5% | ||
| Q3 24 | 6.7% | 6.9% | ||
| Q2 24 | 18.5% | -1.9% |
| Q1 26 | — | — | ||
| Q4 25 | 2.5% | 1.9% | ||
| Q3 25 | 1.9% | 1.3% | ||
| Q2 25 | 0.6% | 1.2% | ||
| Q1 25 | 0.4% | 1.0% | ||
| Q4 24 | 0.1% | 1.9% | ||
| Q3 24 | 0.3% | 1.5% | ||
| Q2 24 | 0.2% | 3.0% |
| Q1 26 | — | — | ||
| Q4 25 | -0.70× | 2.41× | ||
| Q3 25 | 1.63× | 3.46× | ||
| Q2 25 | 0.95× | 0.81× | ||
| Q1 25 | -0.52× | 0.55× | ||
| Q4 24 | 2.05× | — | ||
| Q3 24 | 0.48× | 2.21× | ||
| Q2 24 | 1.41× | 0.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
COCO
| Subtotal | $148.2M | 82% |
| Private Label | $24.4M | 14% |
| Other | $7.2M | 4% |
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
